Satellos Bioscience Inc.

Recent News

  • Satellos Bioscience Announces Development Candidate

    Toronto, Ontario--(Newsfile Corp. - January 3, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has designated SAT-3153 for development towards an IND filing."We are thrilled to be in a position to move SAT-3153 as a novel drug development candidate ("DC") into pre-IND enabling studies in...

    2023-01-03 7:00 AM EST
  • Satellos Bioscience Announces Q3 2022 Financial Results and Operational Highlights

    Toronto, Ontario--(Newsfile Corp. - November 23, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and operational highlights for the quarter ending September 30, 2022. The Company's interim condensed consolidated financial statements for the quarter ended September 30, 2022, and the related management's discussion and analysis (MD&A) are available on SEDAR...

    2022-11-23 5:41 PM EST
  • Satellos Bioscience Announces Advancement of Compounds to Next Stage of Development

    Toronto, Ontario--(Newsfile Corp. - November 3, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company developing therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that it has created, prioritized and advanced novel small molecule drug candidates into further preclinical studies.The Company's compounds have been designed to be potent and selective inhibitors of a particular kinase protein in the Notch pathway which...

    2022-11-03 7:50 AM EDT
  • Satellos Bioscience Inc. to Present Preliminary Preclinical Proof of Concept Data for an Additional Rare Disease at World Muscle Society Meeting

    Toronto, Ontario--(Newsfile Corp. - October 11, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that Ryan Mitchell, PhD and Director of Business Development will present preliminary preclinical proof of concept data in a second rare disease, Congenital muscular dystrophy type 1A. These data will be featured in a poster presentation...

    2022-10-11 7:00 AM EDT
  • Satellos Bioscience Inc. Announces the Grant of Stock Options

    Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today that its board of directors (the "Board") has approved grants of stock options (the "Stock Options") pursuant to the terms of the Company's Stock Option Plan. A total of 813,750 Stock Options have been awarded to directors,...

    2022-10-06 9:00 PM EDT
  • Satellos Bioscience Inc. Announces Licensing of Formulation Technology and Expanded Collaboration with NW PharmaTech Ltd.

    Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Corporation"), is pleased to announce that its wholly owned subsidiary Amphotericin B Technologies Inc. ("AmpB Tech") and NW PharmaTech Ltd. ("NWPT") have today established a joint venture company, NW Micelle Therapeutics Inc. ("NWMT"), for the purpose of developing an oral formulation of cannabidiol for the treatment of insomnia and other indications in the mental health sphere ("Oral CBD"). NWPT will arrange for and provide...

    2022-10-06 5:19 PM EDT
  • Satellos Bioscience Announces OTCQB Listing in the United States

    Toronto, Ontario--(Newsfile Corp. - October 6, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Corporation"), a drug discovery company aimed at developing therapeutics that regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, is pleased to announce that its common shares have commenced trading on the OTCQB Venture Market ("OTCQB") under the symbol "MSCLF". Shares in Satellos will continue to trade on the TSXV under the symbol MSCL."Listing on the...

    2022-10-06 8:18 AM EDT
  • Satellos Bioscience Inc. Announces the Appointment of Philip D. Lambert, Ph.D, as Chief Technology Officer

    Toronto, Ontario--(Newsfile Corp. - September 28, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce that its board of directors (the "Board") has appointed Philip Lambert, Ph.D., as Chief Technology Officer ("CTO") of the Company, effective September 27, 2022. "We are thrilled to welcome Dr. Lambert to our team as CTO, leading our translational research and development...

    2022-09-28 7:30 AM EDT